Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia

Phase 1

Completed

• Conditions: Diabetic Foot; Peripheral Vascular Diseases

• Registration Number: NCT00872326
• Lead Sponsor: Andalusian Network for Design and Translation of Advanced Therapies

Brief Summary

The aim of this study is to assess the efficacy and safety of autologous transplantation of bone-marrow cells for therapeutic angiogenesis and vasculogenesis in diabetic patients with non-revascularizable critical limb ischemia.

Detailed Description

Phase I/II, prospective, single-center study, with consecutive inclusion of 20 diabetic patients with critical limb ischemia due to bellow-the-knee extensive arterial disease.

After the inclusion, patients are submitted to a bone-marrow aspiration (30 ml) under sedation. Autologous bone-marrow mononuclear cells (minimum 80 millions mononuclear cells) are infused intraarterially at popliteal artery by blocking antegrade perfusion during 3 minutes.

Clinical and angiographic follow-up will be performed at 3 months after the infusion to assess the efficacy of autologous mononuclear cells transplantation in terms of:

* Changes in below-the-knee angiography from baseline to 3 months follow-up.

* Changes in Ankle-Brachial pressure Index, transcutaneous oxygen pressure, and size of main ischemic ulcer will be also assessed at target limb.

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2009-03-30
• Study First Submitted QC: 2009-03-30
• Study First Posted: 2009-03-31
• Primary Completion: 2009-04
• Study Completion: 2009-05
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-13
• Last Update Posted: 2014-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Diabetic patients under treatment (type I or II)
• Critical limb ischemia (rest pain and/or non-healing ischemic ulcers lasting more than 4 weeks, and/or Ankle-Brachial Index < 0,8)
• Not suitable to be revascularized (surgical and interventional consensus)

Exclusion Criteria

• Neoplastic disease and/or hematologic disease during the last 2 years
• Diabetic retinopathy
• Ischemic ulcer greater than 10 cm2
• Major amputation at target limb
• Life expectancy > 2 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Angiographic evaluation of angiogenesis and vasculogenesis at target limb	3 months

Secondary Outcome Measures

Name	Time	Method
Ankle-Brachial pressure index	3 months

Trial Locations

Locations (1)

University Hospital Virgen Macarena; 🇪🇸 Seville, Spain